Related by context. All words. (Click for frequent words.) 74 metastatic renal cell carcinoma 73 NSCLC 71 metastatic colorectal cancer 70 hepatocellular carcinoma 69 gastric cancer 68 metastatic melanoma 68 carcinoma 68 solid tumors 68 metastatic 67 malignancies 67 hepatocellular carcinoma HCC 67 metastatic disease 67 neuroendocrine tumors 67 gastrointestinal stromal tumors 67 metastatic breast cancer 66 advanced NSCLC 66 cell carcinoma 66 nonsmall cell lung cancer 66 soft tissue sarcomas 66 pancreatic adenocarcinoma 66 metastatic RCC 66 hepatocellular cancer 66 gastrointestinal stromal tumor GIST 65 chronic lymphocytic leukemia CLL 65 glioblastoma 65 metastatic cancer 65 medullary thyroid cancer 65 mCRC 65 metastatic pancreatic cancer 65 mRCC 65 brain metastases 65 metastatic prostate cancer 65 sorafenib 65 gastrointestinal stromal tumor 65 recurrent NSCLC 65 indolent NHL 64 SCCHN 64 CLL 64 pancreatic NET 64 unresectable 64 cell lung cancer 64 multiple myeloma 64 HER2 positive 64 leukemia AML 64 colorectal cancer 64 follicular lymphoma 64 hormone refractory prostate cancer 64 HER2 positive metastatic breast 64 myelodysplastic syndrome MDS 64 B CLL 63 myelofibrosis 63 systemic lupus erythematosus 63 leukemia CLL 63 lymphoma CTCL 63 non squamous NSCLC 63 stage IIIB 63 lupus nephritis 63 liver metastases 63 lymphomas 63 HER2 positive breast cancer 63 carcinoid tumors 63 metastatic colon cancer 63 basal cell carcinoma BCC 63 squamous cell carcinoma 63 multiple myeloma MM 63 liver cancer 63 Nexavar sorafenib 63 metastatic NSCLC 62 squamous cell cancer 62 acute myelogenous leukemia AML 62 hematologic malignancies 62 malignant pleural mesothelioma 62 DLBCL 62 IV NSCLC 62 IV melanoma 62 adenocarcinoma 62 GIST 62 epithelial tumors 62 HRPC 62 refractory multiple myeloma 62 Amrubicin 62 HNSCC 62 castration resistant prostate cancer 62 Hepatocellular Carcinoma HCC 61 metastases 61 pancreatic cancers 61 carcinomas 61 malignancy 61 leukemia ALL 61 sarcoma 61 acute myeloid leukemia 61 advanced metastatic renal 61 fallopian tube carcinoma 61 metastatic lung cancer 61 sunitinib 61 glioblastoma multiforme GBM 61 Metastatic 61 nonmetastatic 61 receptor tyrosine kinase inhibitor 61 metastatic colorectal 61 cell lymphoma CTCL 61 papillary renal cell carcinoma 61 relapsed refractory multiple myeloma 61 axitinib 61 gastric cancers 61 colorectal cancer CRC 61 pancreatic carcinoma 61 papillary 61 Nexavar tablets 61 metastatic cancers 61 metastatic malignant melanoma 61 breast carcinomas 61 gastrointestinal cancers 61 neoplasm 60 myelodysplastic syndromes MDS 60 bendamustine 60 urothelial carcinoma 60 Hodgkin lymphoma NHL 60 cell lymphomas 60 bladder cancers 60 prostate cancer CRPC 60 distant metastasis 60 non metastatic osteosarcoma 60 metastatic bladder 60 renal tumors 60 cutaneous T cell 60 melanoma 60 heavily pretreated 60 localized prostate cancer 60 temsirolimus 60 colorectal tumors 60 tumors 60 PCa 60 breast carcinoma 60 Renal cell carcinoma 60 GISTs 60 non Hodgkin lymphoma 60 superficial bladder cancer 60 soft tissue sarcoma 60 tumor recurrence 60 advanced hepatocellular carcinoma 60 mCRC patients 60 sorafenib Nexavar ® 60 recurrent glioblastoma multiforme 60 hormone receptor positive 60 adenocarcinomas 60 acute leukemias 60 gastrointestinal stromal tumors GIST 60 ovarian carcinoma 60 invasive candidiasis 60 platinum refractory 60 bone metastasis 60 metastatic gastric 60 stage IIIA 60 distant metastases 60 chronic lymphocytic leukemia 60 epithelial ovarian cancer 60 secondary hyperparathyroidism 60 advanced unresectable 59 colorectal liver metastases 59 sorafenib Nexavar 59 relapsing remitting MS 59 cancers 59 myelodysplastic syndromes 59 myelofibrosis MF 59 neoadjuvant therapy 59 cancer mCRC 59 lobular carcinoma 59 cutaneous melanoma 59 Gleevec resistant 59 metastatic renal cell 59 Proxinium TM 59 malignant lymphoma 59 vandetanib 59 lung tumors 59 metastatic kidney 59 squamous 59 recurrent ovarian cancer 59 osteosarcoma 59 androgen independent 59 sunitinib malate 59 refractory metastatic colorectal cancer 59 relapsed refractory 59 myeloproliferative diseases 59 mucinous 59 metastatic GIST 59 prostate cancers 59 bone metastases 59 neoplasia 59 MALT lymphoma 59 docetaxel chemotherapy 59 cholangiocarcinoma 59 prostate cancer HRPC 59 acute myeloid leukemia AML 59 differentiated thyroid 59 seminoma 59 Acute Myeloid Leukemia AML 59 ccRCC 59 lymphocytic leukemia 59 colorectal carcinoma 59 hematological cancers 59 systemic lupus erythematosus SLE 59 follicular thyroid cancer 59 metastatic carcinoma 59 KRAS wild 59 renal cell carcinomas 59 mTOR inhibitor 59 castrate resistant prostate cancer 59 histologies 59 gemcitabine chemotherapy 59 TEMODAL 59 localized renal 59 Torisel 59 amrubicin 59 pancreatic cancer 59 FOLFIRI 59 Epratuzumab 59 prostate carcinoma 59 chemoradiotherapy 59 relapsing remitting multiple sclerosis 58 sarcomas 58 recurrent colorectal cancer 58 operable breast cancer 58 pheochromocytoma 58 colorectal cancers 58 Glioblastoma 58 squamous cell carcinoma SCC 58 Doxil ® 58 prostate cancer AIPC 58 Metastatic breast cancer 58 pancreatic neuroendocrine tumors 58 Glioblastoma Multiforme 58 candidemia 58 neuroendocrine cancers 58 familial amyloidotic polyneuropathy FAP 58 grade gliomas 58 Carcinoma 58 Non Hodgkin lymphoma 58 endometrioid 58 refractory NSCLC 58 biliary tract cancer 58 lung carcinomas 58 IV metastatic melanoma 58 Li Fraumeni Syndrome 58 resectable 58 refractory AML 58 Surgical resection 58 renal carcinoma 58 tumors GIST 58 anti angiogenic therapy 58 lymphoma 58 thymoma 58 IV malignant melanoma 58 AA amyloidosis 58 resistant ovarian cancer 58 basal cell carcinomas 58 Hodgkin lymphoma HL 58 relapsing remitting 58 cutaneous T 58 lymph node metastases 58 CMV disease 58 neoadjuvant 58 Kit CD# positive 58 medulloblastoma 58 Sorafenib 58 CLL SLL 58 metastatic malignant 58 Acute Myelogenous Leukemia AML 58 myeloproliferative disorders 58 neoplastic lesions 58 serous ovarian cancer 58 Metastatic Colorectal Cancer 58 Genasense ® 58 follicular lymphoma FL 58 recurrent glioblastoma 58 hepatic metastases 58 grade glioma 58 diabetic nephropathy 58 Mantle Cell Lymphoma 58 metastatic lesions 58 relapsed ovarian cancer 58 docetaxel Taxotere ® 58 Wilms tumor 58 situ CIS 58 Cell Lymphoma 58 hypercalcemia 58 gastric carcinoma 58 locoregional 58 Cutaneous T 58 pulmonary metastases 58 metastatic HRPC 58 BRAF inhibitor 58 unresectable liver cancer 58 unresectable tumors 58 neoadjuvant chemotherapy 58 intravesical therapy 57 Cell Lung Cancer 57 relapsed multiple myeloma 57 non squamous 57 hematological malignancies 57 urothelial cancer 57 sorafenib tablets 57 refractory CTCL 57 tyrosine kinase inhibitor 57 follicular NHL 57 gefitinib Iressa 57 prostate cancer mCRPC 57 basal cell carcinoma 57 cell lymphoma ALCL 57 Cholangiocarcinoma 57 endometrial cancers 57 epithelial ovarian 57 Glioblastoma Multiforme GBM 57 nonalcoholic steatohepatitis NASH 57 CHOP chemotherapy 57 prostate adenocarcinoma 57 prostate cancer CaP 57 nasopharyngeal carcinoma 57 liver metastasis 57 HBeAg negative 57 erlotinib Tarceva ® 57 malignant melanoma 57 ovarian cancer 57 EGFR mutations 57 unresectable locally advanced 57 vismodegib 57 depsipeptide 57 carcinoid cancer 57 standard chemotherapy regimens 57 acute myeloid 57 Follicular Lymphoma 57 heavily pretreated patients 57 gastric adenocarcinoma 57 peritoneal carcinomatosis 57 CTCL 57 histologic subtype 57 Irinotecan 57 bladder cancer 57 Halaven 57 mapatumumab 57 essential thrombocythemia 57 stage IIIB IV 57 Follicular lymphoma 57 non Hodgkin lymphomas 57 cell carcinomas 57 thromboembolic events 57 polycythemia vera PV 57 haematological cancers 57 TORISEL 57 PNET 57 mycosis fungoides 57 recurrent prostate cancer 57 chronic ITP 57 astrocytoma 57 unresectable stage 57 breast tumors 57 sarcomatoid 57 ovarian lung 57 erlotinib 57 papillary RCC 57 squamous cell carcinomas 57 curative resection 57 YONDELIS 57 neuroendocrine carcinoma 57 imatinib resistant 57 acute leukemia 57 fludarabine 57 R sorafenib tablets 57 gemcitabine carboplatin 57 eribulin mesylate 57 squamous cell 57 Taxotere ® 57 HuMax CD4 57 refractory ovarian cancer 57 prostate cancer PCa 57 carboplatin paclitaxel 57 proliferative diabetic retinopathy 57 imatinib Gleevec ® 57 CYT# potent vascular disrupting 57 trabectedin 57 relapsed MM 57 malignant gliomas 57 histologically confirmed 57 squamous cell lung cancer 57 completely resected 57 refractory acute myeloid 57 trastuzumab 57 situ LCIS 56 p# biomarker 56 subependymal giant cell 56 rectal cancers 56 activating mutations 56 bladder carcinoma 56 neoadjuvant treatment 56 recurrent metastatic 56 irinotecan chemotherapy 56 metastatic breast 56 taxane chemotherapy 56 EGFR expressing 56 fallopian tube cancers 56 PCNSL 56 liver fibrosis 56 retinoblastoma 56 ependymoma 56 EGFR inhibitors 56 BR.# 56 SUTENT 56 cabazitaxel 56 pazopanib 56 ADVEXIN 56 TKI therapy 56 invasive aspergillosis 56 esophageal cancers 56 SJIA 56 taxane therapy 56 leukaemias 56 anthracycline taxane 56 chemoradiation 56 uveal melanoma 56 plus gemcitabine 56 Diffuse Large B 56 SHPT 56 hematologic disorders 56 Xanafide 56 cisplatin chemotherapy 56 castrate resistant 56 relapsed GBM 56 mutated KRAS gene 56 pegylated liposomal doxorubicin 56 Chronic Lymphocytic Leukemia 56 daunorubicin 56 Velcade bortezomib 56 tumor progression 56 dasatinib Sprycel 56 breast cancers 56 chronic HCV infection 56 idiopathic pulmonary fibrosis IPF 56 lung cancers 56 medically inoperable 56 K ras 56 prostate cancer 56 bevacizumab Avastin 56 vinorelbine 56 KRAS mutations occur 56 Pemetrexed 56 micafungin 56 carcinoid 56 Acute Myeloid Leukemia 56 topotecan 56 hematological malignancy 56 relapsed CLL 56 myelodysplastic syndrome 56 azacitidine 56 Afinitor 56 Chronic Lymphocytic Leukemia CLL 56 metastatic renal 56 carcinoma HCC 56 panobinostat 56 lymphoproliferative disorders 56 lung metastases 56 lumiliximab 56 esophageal adenocarcinoma 56 bevacizumab Avastin ® 56 Chronic lymphocytic leukemia 56 Burkitt lymphoma 56 stage IIIb IV 56 HCV infection 56 essential thrombocythemia ET 56 cervical carcinoma 56 myeloproliferative neoplasms 56 leukemias lymphomas 56 anti leukemic 56 esophageal carcinoma 56 EGFR mutation 56 TACE 56 imatinib Gleevec 56 Annamycin 56 colon cancer 56 Aplidin 56 TTF Therapy 56 Multiple Myeloma MM 56 superficial basal cell carcinoma 56 invasive bladder 56 docetaxel Taxotere R 56 transthyretin amyloidosis 56 Tamibarotene 56 endometrial cancer 56 neoplasms 56 refractory APL 56 metastatic tumors 56 homozygous familial hypercholesterolemia 56 Everolimus 56 clinically localized prostate 56 prognostic variables 56 HGS ETR1 56 metastatic squamous cell carcinoma 56 pertuzumab 56 lymph node involvement 56 cytokine refractory 56 cytotoxic chemotherapy 56 malignant neoplasms 56 Voreloxin 56 invasive fungal infections 56 refractory CLL 56 alvespimycin 56 metastatic HER2 positive 56 histological subtype 56 transitional cell carcinoma 55 Ceflatonin 55 KRAS mutation 55 NAFLD 55 demonstrated antitumor activity 55 chlorambucil 55 relapsed SCLC 55 tumor xenograft models 55 small lymphocytic lymphoma 55 parathyroid carcinoma 55 Acute myeloid leukemia 55 aHUS 55 CaP 55 ADPKD 55 cell lymphoma 55 adjuvant therapy 55 hepatorenal syndrome 55 Evoltra ® 55 Cloretazine 55 cetuximab Erbitux R 55 Bayer Nexavar 55 cediranib 55 phase IIb clinical 55 prostate tumor 55 grade cervical intraepithelial 55 leiomyosarcoma 55 smoldering myeloma 55 metastasis 55 non resectable 55 EGFr 55 cilengitide 55 HSCT 55 Papillary 55 invasive ductal 55 malignant tumors 55 dasatinib 55 premalignant 55 Soft Tissue Sarcoma 55 urothelial bladder cancer 55 lymphoid malignancies 55 nonmelanoma skin cancers 55 Taxotere R 55 chronic HCV 55 Myelofibrosis 55 alkylating agent 55 Non Hodgkin Lymphoma 55 metastatic CRC 55 recurrent GBM 55 BARACLUDE ® 55 BAY #-# 55 endometrial hyperplasia 55 Gastric cancer 55 K ras mutations 55 cutaneous squamous cell carcinoma 55 cetuximab 55 EGFR 55 Aflibercept 55 Dasatinib 55 preoperative chemotherapy 55 tumor lysis syndrome 55 pediatric acute lymphoblastic 55 mutated KRAS 55 chronic plaque psoriasis 55 polyp recurrence 55 biologic therapy 55 FOLOTYN 55 anaplastic astrocytoma 55 Renal Cell Carcinoma RCC 55 decitabine 55 papillary thyroid cancer 55 sunitinib Sutent 55 symptomatic BPH 55 LHRH receptor positive 55 recurrent malignant glioma 55 chemotherapeutic agent 55 multi kinase inhibitor 55 Fludara ® 55 rhabdomyosarcoma 55 Hodgkin Lymphoma 55 dacarbazine DTIC 55 Lenalidomide 55 HGPIN 55 adecatumumab 55 temozolomide 55 chemotherapeutic regimen 55 paclitaxel Taxol R 55 metastatic relapsed 55 invasive breast cancer 55 proteasome inhibitor 55 anti EGFR antibody 55 AA Amyloidosis 55 IIIB NSCLC 55 hypereosinophilic syndrome 55 Gleevec imatinib mesylate 55 metastatic neuroendocrine tumors 55 posaconazole 55 bortezomib 55 anaplastic 55 RoACTEMRA 55 chemoresistant 55 aflibercept VEGF Trap 55 squamous histology 55 thalidomide Thalomid 55 Fludara 55 remission induction 55 rheumatoid arthritis RA 55 stage IIIb 55 MabCampath 55 MYLOTARG 55 Folfox 55 Zolinza 55 skeletal metastases 55 node metastases 55 xenograft models 55 castration resistant 55 vemurafenib 55 colorectal lung 55 Perifosine 55 Tarceva TM 55 chemotherapeutic regimens 55 myelofibrosis polycythemia vera 55 panitumumab Vectibix 55 synovial sarcoma 55 MGUS 55 osteosarcomas 55 Erbitux cetuximab 55 EGFR expressing mCRC 55 ovarian cancers 55 KRAS status 55 interstitial pneumonia 55 Vectibix 55 colorectal cancer liver metastases 55 glioblastomas 55 TNF antagonist 55 geographic atrophy 55 Imprime PGG 55 concurrent chemoradiation 55 invasive ductal carcinoma 55 acute lymphoblastic leukemia 55 tivozanib 55 ErbB2 positive 55 squamous cell cancers 55 acute GvHD 55 Renal Cell Carcinoma 55 Hematologic 55 idarubicin 55 follicular lymphomas 55 PD LID 55 metastatic pancreatic 55 atypical Hemolytic Uremic Syndrome 55 mycophenolate mofetil 55 metastatic castration resistant 55 Allovectin 7 ® 55 neovascular AMD 55 hematologic cancers 55 chronic myeloid leukemia CML 55 acute myelogenous 55 factor receptor EGFR 55 irinotecan containing 55 atypical hemolytic uremic syndrome 55 ductal breast cancer 55 cytoreductive nephrectomy 55 refractory colorectal cancer 55 recurrent glioblastoma multiforme GBM 55 Nexavar ® 55 relapsing remitting MS RRMS 55 dacarbazine 55 Telintra 55 Rituxan rituximab 55 INCB# [003] 55 leukemias 55 Folotyn 55 Anaplastic 55 PANVAC VF 55 evaluating tivozanib 55 Barrett esophagus 54 hereditary antithrombin deficiency 54 juvenile idiopathic arthritis JIA 54 hypomethylating agents 54 Crohn disease 54 FOLFOX6 54 colorectal 54 inoperable pancreatic cancer 54 Erlotinib 54 bladder tumors 54 metastatic hormone refractory 54 chronic HBV 54 severe neutropenia 54 refractory prostate cancer 54 T1DM 54 acute promyelocytic leukemia APL 54 Raf MEK ERK 54 metachronous 54 nucleoside analog 54 myeloablative 54 systemic fungal infections 54 chronic ITP patients 54 Faslodex 54 Dacogen injection 54 Hodgkin lymphoma 54 Atiprimod 54 Bortezomib 54 lung pancreatic 54 Alemtuzumab 54 pralatrexate 54 opioid induced constipation OIC 54 refractory indolent non 54 autoantibody positive 54 intestinal metaplasia 54 pancreatic tumor 54 Relapsed Refractory 54 metastatic basal cell 54 pleural mesothelioma 54 locoregional recurrence 54 Vandetanib 54 docetaxel Taxotere 54 colorectal adenomas 54 BCG refractory 54 Toxicities 54 severe sepsis 54 cytoreduction 54 neuroblastoma 54 regorafenib 54 HER2 negative 54 HER2 + 54 liposomal amphotericin B 54 gemcitabine Gemzar 54 IL# PE#QQR 54 Myelodysplastic Syndrome MDS 54 chemotherapy regimens 54 angiosarcoma 54 cell chronic lymphocytic 54 myeloma 54 HER2 positive cancers 54 Myelodysplastic Syndrome 54 chemotherapy cisplatin 54 ovarian tumors 54 angiogenesis inhibitor 54 INCB# [002] 54 Adjuvant chemotherapy 54 GvHD 54 DMARD 54 T2DM 54 anthracyclines 54 chronic myeloid 54 AEG# 54 tyrosine kinase inhibitors TKIs 54 JMML 54 anticancer therapy 54 melanomas 54 non Hodgkin Lymphoma 54 gliomas 54 myeloproliferative disorder 54 Vicinium TM 54 relapsing MS 54 EFAPROXYN 54 imatinib therapy 54 adenomas 54 Acute Coronary Syndromes ACS 54 adenoma 54 eribulin 54 haematological malignancies 54 pleomorphic 54 diagnosed glioblastoma multiforme 54 TREANDA 54 NMIBC 54 Tavocept 54 cell acute lymphoblastic 54 assessing T DM1 54 luteinizing hormone releasing 54 bevacizumab 54 prostate pancreatic 54 peritoneal cancer 54 docetaxel 54 MGd 54 gemcitabine 54 NovoTTF 54 Nilotinib 54 lymphoblastic leukemia 54 monotherapy 54 cetuximab Erbitux 54 biliary strictures 54 tigecycline 54 KRAS mutant tumors 54 Phase #/#a trial 54 tumor subtypes 54 HER2 overexpression 54 IRESSA 54 cell malignancies 54 DMARDs 54 paclitaxel carboplatin 54 non metastatic resectable 54 colon carcinoma 54 tyrosine kinase inhibitors 54 pancreatic insufficiency 54 EOquin 54 metastatic liver 54 endometrial adenocarcinoma 54 Zarnestra 54 HER2 54 inhibitor RG# 54 Acute lymphoblastic leukemia 54 refractory cutaneous T 54 pancreatic 54 vidofludimus 54 lymphadenectomy 54 fibromyalgia syndrome 54 astrocytomas 54 advanced epithelial ovarian 54 Fludarabine 54 Sezary syndrome 54 hormone refractory metastatic prostate 54 situ DCIS 54 systemic ALCL 54 tumor 54 allogeneic bone marrow 54 EGFR mutation positive 54 refractory Hodgkin lymphoma 54 OncoVEX GM CSF 54 Osteosarcoma 54 FOLFOX regimen 54 dasatinib Sprycel ® 54 leukemia APL 54 advanced adenoma 54 papillary thyroid carcinoma 54 IgG1 monoclonal antibody 54 mesotheliomas 54 CTAP# Capsules 54 chemotherapy regimen 54 mTOR inhibitors 54 refractory chronic lymphocytic 54 ALCL 54 common hematologic malignancy 54 lenalidomide Revlimid R 54 chronic HBV infection 54 adjuvant radiotherapy 54 previously untreated follicular 54 PEGylated interferon beta 1a 54 hepatitis C genotype 54 Xelox 54 EpCAM 54 medulloblastomas 54 eculizumab 54 SUTENT ® 54 colon lung 54 Vidaza azacitidine 54 CIN3 54 Atypical Hemolytic Uremic Syndrome 54 diagnosed multiple myeloma 54 advanced adenomas 54 imatinib 54 IBS C 54 rituximab 54 hypercholesterolemia 54 Alessandro Riva 54 ara C 54 metastatic adenocarcinoma 54 paraganglioma 54 fibrosis 54 glufosfamide 54 carcinoma HNSCC 54 Dapagliflozin 54 iniparib 54 Hepatocellular Carcinoma 54 Bezielle 54 Waldenstrom macroglobulinemia 54 metastatic ovarian cancer 54 histological subtypes 54 atherothrombotic events 54 nodal metastasis 54 tocilizumab 54 colon cancers 54 acute PAO 54 AML MDS 54 adjuvant radiation 54 efalizumab 54 fluoropyrimidine 53 BRIM2 53 paragangliomas 53 Cloretazine R 53 hepatoma 53 radical nephrectomy 53 elacytarabine 53 Miraxion 53 multikinase inhibitor 53 thymic carcinoma 53 syngeneic 53 juvenile idiopathic arthritis 53 papillary carcinoma 53 Advexin 53 IIIA NSCLC 53 idiopathic pulmonary fibrosis 53 cinacalcet 53 antitumor effect 53 ToGA 53 colorectal liver 53 cSSSI 53 T#I mutation 53 metastatic castrate resistant 53 LHRH antagonists 53 pancreatic colon 53 perifosine 53 precancerous cervical lesions 53 T#I [002] 53 Sutent sunitinib 53 epithelial cancers 53 cytotoxic therapy 53 microsphere therapy 53 radiofrequency ablation RFA 53 Plicera 53 Seliciclib 53 ulcerative colitis 53 malignant pancreatic 53 severe oral mucositis 53 BRAF V#E mutation 53 OMAPRO 53 MELAS 53 Adenocarcinoma 53 brain tumor glioblastoma multiforme 53 MPGN 53 olaparib 53 Chronic Myeloid Leukemia 53 kidney urologic 53 relapsed leukemia 53 periodontitis 53 acute coronary syndromes ACS 53 infusional 5-FU/LV 53 TTR amyloidosis 53 GIST tumors 53 5 fluorouracil 53 pituitary adenomas 53 Amigal 53 idiopathic myelofibrosis 53 lung adenocarcinomas 53 sodium thiosulfate STS 53 vWD 53 HCV genotype 53 hepatocellular carcinomas 53 R0 resection 53 Basal cell 53 gemcitabine Gemzar ® 53 galiximab 53 mitomycin 53 prostatic adenocarcinoma 53 liposomal doxorubicin 53 pain palliation 53 Vidofludimus 53 Arranon 53 plus dexamethasone 53 retinal vein occlusion 53 colorectal adenoma 53 untreated multiple myeloma 53 follicular non 53 pomalidomide 53 refractory metastatic 53 chronic renal failure 53 pulmonary arterial hypertension PAH 53 nodular BCC 53 GW# [003] 53 Idiopathic Pulmonary Fibrosis 53 chemoradiation therapy 53 idiopathic thrombocytopenic purpura ITP 53 AVASTIN 53 vinca alkaloids 53 Squamous 53 interferon alfa 53 PNP inhibitor 53 Glioblastoma multiforme GBM 53 systemic anaplastic large 53 paroxysmal nocturnal hemoglobinuria PNH 53 laryngeal cancer 53 invasive carcinoma 53 placebo controlled clinical 53 immune thrombocytopenic purpura ITP 53 decompensated liver disease 53 glioblastoma multiforme 53 pediatric malignancies 53 pT2 53 ZACTIMA 53 glioma 53 tumor metastases 53 1 diabetes T1D 53 BRAF mutations 53 somatostatin analogues 53 TRISENOX 53 FLT3 53 TYKERB 53 colorectal pancreatic 53 malignant fibrous histiocytoma 53 HBeAg positive 53 Xcytrin 53 non alcoholic steatohepatitis